Label: KAYEXALATE- sodium polystyrene sulfonate powder, for suspension 

  • Label RSS
  • NDC Code(s): 24987-075-01
  • Packager: Covis Pharmaceuticals, Inc.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Drug Application

Drug Label Information

Updated 08/13

If you are a consumer or patient please visit this version.

  • DESCRIPTION

    KAYEXALATE, brand of sodium polystyrene sulfonate is a benzene, diethenyl-polymer, with ethenylbenzene, sulfonated, sodium salt and has the following structural formula:

    Chemical Structure

    The drug is a cream to light brown finely ground, powdered form of sodium polystyrene sulfonate, a cation-exchange resin prepared in the sodium phase with an in vitro exchange capacity of approximately 3.1 mEq (in vivo approximately 1 mEq) of potassium per gram. The sodium content is approximately 100 mg (4.1 mEq) per gram of the drug. It can be administered orally or in an enema.

    Close
  • CLINICAL PHARMACOLOGY

    As the resin passes along the intestine or is retained in the colon after administration by enema, the sodium ions are partially released and are replaced by potassium ions. For the most part, this action occurs in the large intestine, which excretes potassium ions to a greater degree than does the small intestine. The efficiency of this process is limited and unpredictably variable. It commonly approximates the order of 33 percent but the range is so large that definitive indices of electrolyte balance must be clearly monitored.

    Metabolic data are unavailable.

    Close
  • INDICATION AND USAGE

    KAYEXALATE is indicated for the treatment of hyperkalemia.

    Close
  • CONTRAINDICATIONS

    KAYEXALATE is contraindicated in the following conditions: patients with hypokalemia, patients with a history of hypersensitivity to polystyrene sulfonate resins, obstructive bowel disease, neonates with reduced gut motility (postoperatively or drug induced) and oral administration in neonates (see PRECAUTIONS).

    Close
  • WARNINGS

    Intestinal Necrosis

    Cases of intestinal necrosis, which may be fatal, and other serious gastrointestinal adverse events (bleeding, ischemic colitis, perforation) have been reported in association with KAYEXALATE use. The majority of these cases reported the concomitant use of sorbitol. Risk factors for gastrointestinal adverse events were present in many of the cases including prematurity, history of intestinal disease or surgery, hypovolemia, and renal insufficiency and failure. Concomitant administration of sorbitol is not recommended (see PRECAUTIONS, Drug Interactions).

    • Use only in patients who have normal bowel function. Avoid use in patients who have not had a bowel movement post-surgery.
    • Avoid use in patients who are at risk for developing constipation or impaction (including those with history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, or bowel obstruction).
    • Discontinue use in patients who develop constipation.

    Alternative Therapy in Severe Hyperkalemia

    Since effective lowering of serum potassium with KAYEXALATE may take hours to days, treatment with this drug alone may be insufficient to rapidly correct severe hyperkalemia associated with states of rapid tissue breakdown (e.g., burns and renal failure) or hyperkalemia so marked as to constitute a medical emergency. Therefore, other definitive measures, including dialysis, should always be considered and may be imperative.

    Hypokalemia

    Serious potassium deficiency can occur from therapy with KAYEXALATE. The effect must be carefully controlled by frequent serum potassium determinations within each 24 hour period. Since intracellular potassium deficiency is not always reflected by serum potassium levels, the level at which treatment with KAYEXALATE should be discontinued must be determined individually for each patient. Important aids in making this determination are the patient's clinical condition and electrocardiogram. Early clinical signs of severe hypokalemia include a pattern of irritable confusion and delayed thought processes.

    Electrocardiographically, severe hypokalemia is often associated with a lengthened Q-T interval, widening, flattening, or inversion of the T wave, and prominent U waves. Also, cardiac arrhythmias may occur, such as premature atrial, nodal, and ventricular contractions, and supraventricular and ventricular tachycardias. The toxic effects of digitalis are likely to be exaggerated. Marked hypokalemia can also be manifested by severe muscle weakness, at times extending into frank paralysis.

    Electrolyte Disturbances

    Like all cation-exchange resins, KAYEXALATE is not totally selective (for potassium) in its actions, and small amounts of other cations such as magnesium and calcium can also be lost during treatment. Accordingly, patients receiving KAYEXALATE should be monitored for all applicable electrolyte disturbances.

    Systemic Alkalosis

    Systemic alkalosis has been reported after cation-exchange resins were administered orally in combination with nonabsorbable cation-donating antacids and laxatives such as magnesium hydroxide and aluminum carbonate. Magnesium hydroxide should not be administered with KAYEXALATE. One case of grand mal seizure has been reported in a patient with chronic hypocalcemia of renal failure who was given KAYEXALATE with magnesium hydroxide as laxative. (See PRECAUTIONS, Drug Interactions.)

    Close
  • PRECAUTIONS

    Caution is advised when KAYEXALATE is administered to patients who cannot tolerate even a small increase in sodium loads (i.e., severe congestive heart failure, severe hypertension, or marked edema). In such instances compensatory restriction of sodium intake from other sources may be indicated.

    In the event of clinically significant constipation, treatment with KAYEXALATE should be discontinued until normal bowel motion is resumed (see WARNINGS, Intestinal Necrosis).

    Drug Interactions

    Antacids

    The simultaneous oral administration of KAYEXALATE with nonabsorbable cation-donating antacids and laxatives may reduce the resin's potassium exchange capability.

    Non-absorbable cation-donating antacids and laxatives

    Systemic alkalosis has been reported after cation-exchange resins were administered orally in combination with nonabsorbable cation-donating antacids and laxatives such as magnesium hydroxide and aluminum carbonate. Magnesium hydroxide should not be administered with KAYEXALATE. One case of grand mal seizure has been reported in a patient with chronic hypocalcemia of renal failure who was given KAYEXALATE with magnesium hydroxide as a laxative.

    Intestinal obstruction due to concretions of aluminum hydroxide when used in combination with KAYEXALATE has been reported.

    Digitalis

    The toxic effects of digitalis on the heart, especially various ventricular arrhythmias and A-V nodal dissociation, are likely to be exaggerated by hypokalemia, even in the face of serum digoxin concentrations in the "normal range". (See WARNINGS.)

    Sorbitol

    Concomitant use of Sorbitol with KAYEXALATE has been implicated in cases of intestinal necrosis, which may be fatal. Therefore, concomitant administration is not recommended. (See WARNINGS.)

    Lithium

    KAYEXALATE may decrease absorption of lithium.

    Thyroxine

    KAYEXALATE may decrease absorption of thyroxine.

    Carcinogenesis, Mutagenesis, Impairment of Fertility

    Studies have not been performed.

    Pregnancy Category C

    Animal reproduction studies have not been conducted with KAYEXALATE. It is also not known whether KAYEXALATE can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. KAYEXALATE should be given to a pregnant woman only if clearly needed.

    Nursing Mothers

    It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when KAYEXALATE is administered to a nursing woman.

    Pediatric Use

    The effectiveness of KAYEXALATE in pediatric patients has not been established. In neonates, KAYEXALATE should not be given by the oral route. In both children and neonates particular care should be observed with rectal administration, as excessive dosage or inadequate dilution could result in impaction of the resin.

    Due to the risk of digestive hemorrhage or intestinal necrosis, particular care should be observed in premature infants or low birth weight infants.

    Close
  • ADVERSE REACTIONS

    KAYEXALATE may cause some degree of gastric irritation. Anorexia, nausea, vomiting, and constipation may occur especially if high doses are given. Also, hypokalemia, hypocalcemia, hypomagnesemia and significant sodium retention, and their related clinical manifestations, may occur (see WARNINGS). Occasionally diarrhea develops. Large doses in elderly individuals may cause fecal impaction (see PRECAUTIONS). Rare instances of intestinal necrosis have been reported. Intestinal obstruction due to concretions of aluminum hydroxide, when used in combination with KAYEXALATE, has been reported.

    The following events have been reported from worldwide post marketing experience:

    • Fecal impaction following rectal administration, particularly in children;
    • Gastrointestinal concretions (bezoars) following oral administration;
    • Ischemic colitis, gastrointestinal tract ulceration or necrosis which could lead to intestinal perforation; and,
    • Rare cases of acute bronchitis and/or broncho-pneumonia associated with inhalation of particles of polystyrene sulfonate.
    Close
  • OVERDOSAGE

    Overdosage may result in electrolyte disturbances including hypokalemia, hypocalcemia, and hypomagnesemia. Biochemical disturbances resulting from overdosage may give rise to clinical signs and symptoms of hypokalemia, including: irritability, confusion, delayed thought processes, muscle weakness, hyporeflexia, which may progress to frank paralysis and/or apnea. Tetany may occur. Electrocardiographic changes may be consistent with hypokalemia or hypocalcemia; cardiac arrhythmias may occur. Appropriate measures should be taken to correct serum electrolytes (potassium, calcium, magnesium), and the resin should be removed from the alimentary tract by appropriate use of laxatives or enemas.

    Close
  • DOSAGE AND ADMINISTRATION

    Suspension of this drug should be freshly prepared and not stored beyond 24 hours.

    The average daily adult dose of the resin is 15 g to 60 g. This is best provided by administering 15 g (approximately 4 level teaspoons) of KAYEXALATE one to four times daily. One gram of KAYEXALATE contains 4.1 mEq of sodium; one level teaspoon contains approximately 3.5 g of KAYEXALATE and 15 mEq of sodium. (A heaping teaspoon may contain as much as 10 g to 12 g of KAYEXALATE.) Since the in vivo efficiency of sodium-potassium exchange resins is approximately 33 percent, about one third of the resin's actual sodium content is being delivered to the body.

    In smaller children and infants, lower doses should be employed by using as a guide a rate of 1 mEq of potassium per gram of resin as the basis for calculation.

    Each dose should be given as a suspension in a small quantity of water or, for greater palatability, in syrup. The amount of fluid usually ranges from 20 mL to 100 mL, depending on the dose, or may be simply determined by allowing 3 mL to 4 mL per gram of resin. Healthcare professionals should follow full aspiration precautions when administering this product, such as placing and maintaining the patient in an upright position while the resin is being administered.

    The resin may be introduced into the stomach through a plastic tube and, if desired, mixed with a diet appropriate for a patient in renal failure.

    The resin may also be given, although with less effective results, in an enema consisting (for adults) of 30 g to 50 g every six hours. Each dose is administered as a warm emulsion (at body temperature) in 100 mL of aqueous vehicle. The emulsion should be agitated gently during administration. The enema should be retained as long as possible and followed by a cleansing enema.

    After an initial cleansing enema, a soft, large size (French 28) rubber tube is inserted into the rectum for a distance of about 20 cm, with the tip well into the sigmoid colon, and taped in place. The resin is then suspended in the appropriate amount of aqueous vehicle at body temperature and introduced by gravity, while the particles are kept in suspension by stirring. The suspension is flushed with 50 mL or 100 mL of fluid, following which the tube is clamped and left in place. If back leakage occurs, the hips are elevated on pillows or a knee-chest position is taken temporarily. A somewhat thicker suspension may be used, but care should be taken that no paste is formed, because the latter has a greatly reduced exchange surface and will be particularly ineffective if deposited in the rectal ampulla. The suspension is kept in the sigmoid colon for several hours, if possible. Then, the colon is irrigated with nonsodium containing solution at body temperature in order to remove the resin. Two quarts of flushing solution may be necessary. The returns are drained constantly through a Y tube connection. While the use of sorbitol is not recommended, particular attention should be paid to this cleansing enema if sorbitol has been used.

    The intensity and duration of therapy depend upon the severity and resistance of hyperkalemia.

    KAYEXALATE should not be heated for to do so may alter the exchange properties of the resin.

    Close
  • HOW SUPPLIED

    KAYEXALATE is available as a cream to light brown, finely ground powder in jars of 1 pound (453.6 g), NDC 24987-075-01.

    Store at 25° C (77° F); excursions permitted to 15° – 30° C (59° – 86° F) [see USP Controlled Room Temperature]

    Close
  • SPL UNCLASSIFIED SECTION

    Rx Only

    Distributed by
    Covis Pharmaceuticals, Inc.
    Cary, NC 27511

    © 2013 Covis Pharmaceuticals, Inc. All rights reserved.

    Revised April 2013

    Close
  • PRINCIPAL DISPLAY PANEL - 453.6 g Jar

    NDC 24987-075-01         K-450           Rx only

    Kayexalate®
    sodium polystyrene
    sulfonate, USP

                                              Read package insert.

    Average adult dose: 15 g (approximately 4 level
    teaspoons) one to four time daily in water. See
    complete prescribing information.

    The effect must be carefully controlled by frequent
    serum potassium determinations within each 24 hour
    period. Sodium content approximately 60 mEq per 15 g.

    Suspension should be freshly prepared and not
    stored beyond 24 hours. dispense in tight, light-
    resistant containers as defined in the official
    compendia.

    Store at 25°C (77°F); excursions permitted to
    15°–30°C (59°–86°F) [see USP Controlled Room
    Temperature].

    Mfd. for: Covis Pharmaceuticals, Inc., Cary, NC 27511
    Origin Canada   © 2013 Covis Pharmaceuticals, Inc.
    100111        Rev. 4/13

    Jar Label
    Close
  • INGREDIENTS AND APPEARANCE
    KAYEXALATE 
    sodium polystyrene sulfonate powder, for suspension
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:24987-075
    Route of Administration ORAL, RECTAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    SODIUM POLYSTYRENE SULFONATE (POLYSTYRENE SULFONIC ACID) SODIUM CATION 4.1 meq  in 1 g
    Product Characteristics
    Color BROWN (cream to light brown) Score     
    Shape Size
    Flavor Imprint Code
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:24987-075-01 453.6 g in 1 JAR
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA011287 07/15/2013
    Labeler - Covis Pharmaceuticals, Inc. (969968986)
    Close